Vaccination with the COVID-19 vaccine is still an important means to establish a universal immunity barrier, block the spread of the COVID-19 virus (SARS-CoV-2), and reduce the rate of critical illness and mortality after infection with SARS-CoV-2 under the current normalization of epidemic prevention and control. However, the safety and effectiveness of vaccination in people with underlying diseases has always been a matter of great concern. As a serious liver disease, liver cancer has limited data on the safety and immunogenicity of COVID-19 vaccines for patients with liver cancer.
This study prospectively enrolled 74 liver cancer patients with no previous history of SARS-CoV-2 infection from 10 hospitals in the CHESS-NMCID collaboration group from January 2021 to December 2021. All liver cancer patients were vaccinated with two doses of the domestically produced inactivated COVID-19 vaccine, and serum samples were collected at least 14 days after the second dose of vaccine, and SARS-CoV-2 neutralizing antibodies were detected using chemiluminescence immunoassay (Shenzhen Mindray SARS-CoV -2 Neutralizing Antibody Quantitative Detection Kit).
Research shows that in terms of safety, a total of 12.2% (9/74) of patients experienced at least 1 adverse reaction after receiving the COVID-19 vaccine. All adverse reactions were mild self-limiting reactions, including pain at the injection site [(6.8 % (5/74)] and anorexia [2.7% (2/74)] were the most common local and systemic adverse reactions, respectively.
In terms of immunogenicity, at a median time of 45 days after the second dose of vaccine, The median SARS-CoV-2 neutralizing antibody level of all liver cancer patients was 13.5 (interquartile range 6.9-23.2) AU/mL, and the SARS-CoV-2 neutralizing antibody positive rate (10 AU/mL) was 60.8 % (45/74), the median level of neutralizing antibody in 45 patients with neutralizing antibody-positive liver cancer was 19.3 (interquartile range 15.0-38.3) AU/mL
This study showed that patients with liver cancer vaccinated with SARS- The safety of the CoV-2 inactivated vaccine is good, but its immune response is weaker than that of healthy people. Considering that the potential benefits of injecting domestically produced inactivated COVID-19 vaccines outweigh the risks for liver cancer patients, it is recommended that Chinese liver cancer patients should be vaccinated as much as possible if there are no other contraindications.
▌Original link:
https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.27992
